
News|Articles|August 1, 2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
El Niño and La Niña Affect Eye Health Too, Not Just Weather | AAO 2025
2
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
3
Eylea HD Provides Vision Gains and Longer Dosing Intervals in Real-World Analysis | AAO 2025
4
Real-World Data Shows Vision Decline as Copay Programs Run Dry | AAO 2025
5